Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure

•Treatment-naive and relapsed/refractory MDS patients receiving venetoclax and HMAs have an ORR of 59% with 63% of responders proceeding to transplant.•Allogeneic stem cell transplantation after treatment with venetoclax in combination with HMA is associated with prolonged survival. [Display omitted...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood advances 2020-07, Vol.4 (13), p.2866-2870
Hauptverfasser:	Ball, Brian J., Famulare, Christopher A., Stein, Eytan M., Tallman, Martin S., Derkach, Andriy, Roshal, Mikhail, Gill, Saar I., Manning, Benjamin M., Koprivnikar, Jamie, McCloskey, James, Testi, Rebecca, Prebet, Thomas, Al Ali, Najla H., Padron, Eric, Sallman, David A., Komrokji, Rami S., Goldberg, Aaron D.
Format:	Artikel
Sprache:	eng
Schlagworte:	Bridged Bicyclo Compounds, Heterocyclic - therapeutic use Humans Stimulus Report Sulfonamides - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	•Treatment-naive and relapsed/refractory MDS patients receiving venetoclax and HMAs have an ORR of 59% with 63% of responders proceeding to transplant.•Allogeneic stem cell transplantation after treatment with venetoclax in combination with HMA is associated with prolonged survival. [Display omitted]
ISSN:	2473-9529 2473-9537 2473-9537
DOI:	10.1182/bloodadvances.2020001482